Last updated: February 19, 2026
Executive Summary
Novo Nordisk Inc. filed suit against Sandoz Inc. on April 20, 2020, in the U.S. District Court for the District of New Jersey, alleging patent infringement. The dispute centers on Sandoz's proposed generic version of Novo Nordisk's diabetes medication, Victoza (liraglutide). Novo Nordisk asserts that Sandoz's product infringes on its U.S. Patent No. 7,960,390. Sandoz has challenged the validity of this patent. The litigation involves complex issues of patent law, including obviousness and anticipation. As of the latest available filings, the parties are engaged in pre-trial proceedings, including discovery and claim construction.
What is the core of the litigation between Novo Nordisk and Sandoz?
The litigation primarily concerns Sandoz's proposed Abbreviated New Drug Application (ANDA) for a generic version of Novo Nordisk's Victoza (liraglutide). Novo Nordisk claims that Sandoz's ANDA infringes U.S. Patent No. 7,960,390, which covers aspects of liraglutide. Sandoz, in response, has challenged the validity of this patent, asserting that it is either anticipated by prior art or would have been obvious to a person skilled in the art at the time of invention. The '390 patent is a key asset for Novo Nordisk protecting its blockbuster diabetes drug.
Which specific patent is at issue in this case?
The central patent in this dispute is U.S. Patent No. 7,960,390, titled "Glucagon-like peptide-1 receptor agonists." This patent was issued on June 14, 2011. The patent claims relate to liraglutide and its therapeutic uses. Novo Nordisk alleges that Sandoz's proposed generic product infringes claims 1, 2, 5, 11, 12, 13, 14, and 15 of this patent. [1]
What are Sandoz's primary defenses?
Sandoz's primary defenses against Novo Nordisk's infringement claims are based on challenging the validity of U.S. Patent No. 7,960,390. Specifically, Sandoz argues that the patent is invalid because:
- Anticipation: The claimed invention is not novel and was already disclosed in prior art before the effective filing date of the patent. [2]
- Obviousness: Even if not directly anticipated, the claimed invention would have been obvious to a person of ordinary skill in the art at the time of the invention, considering the existing prior art. [2]
Sandoz has presented arguments and evidence to support these invalidity defenses, aiming to clear the path for its generic liraglutide product.
What is the market significance of Victoza?
Victoza is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk for the treatment of type 2 diabetes. It is also approved for reducing the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Victoza generated global sales of approximately DKK 43.2 billion (approximately $6.3 billion USD at current exchange rates) in 2022, making it a highly significant product for Novo Nordisk's revenue stream. [3] The potential market entry of a generic version poses a substantial threat to these sales.
What is the procedural status of the litigation?
The litigation, docketed as 1:20-cv-00747, is proceeding in the U.S. District Court for the District of New Jersey. As of the latest available public dockets, the case is in the pre-trial phase. Key procedural steps have included:
- Complaint Filing: Novo Nordisk filed its complaint on April 20, 2020. [1]
- Answer and Counterclaims: Sandoz filed its answer and counterclaims, asserting patent invalidity, on July 27, 2020. [2]
- Claim Construction: The parties have engaged in the Markman process, where the court interprets the meaning and scope of the patent claims. This is a critical step in patent litigation, as claim construction often dictates the outcome of infringement and validity issues.
- Discovery: Both parties are conducting discovery, which includes exchanging documents, taking depositions, and gathering evidence to support their respective positions.
- Motions: Various pre-trial motions may have been filed or are anticipated, including motions for summary judgment.
The case is actively managed by the court, and a trial date has not yet been set, pending the resolution of claim construction and other pre-trial matters.
What is the legal basis for Novo Nordisk's infringement claim?
Novo Nordisk's infringement claim is based on the U.S. Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act. Under this act, a company seeking to market a generic drug must file an ANDA. When filing an ANDA, the applicant must certify that the patent(s) listed in the FDA's Orange Book for the reference listed drug are either expired, will expire, have been invalidated, or will not be infringed by the generic product.
Sandoz filed an ANDA for its generic liraglutide. Novo Nordisk alleges that this ANDA constitutes an act of infringement under 35 U.S.C. § 271(e)(2)(A) because Sandoz has represented that its generic drug does not infringe the '390 patent, while Novo Nordisk contends it does. The dispute hinges on whether Sandoz's proposed generic product falls within the scope of one or more of the asserted claims of U.S. Patent No. 7,960,390. [1]
How does the doctrine of obviousness-type double patenting apply or potentially apply?
While not explicitly detailed as a primary defense in the initial filings, the doctrine of obviousness-type double patenting is a common challenge in pharmaceutical patent litigation, especially when a patent is asserted against a generic challenger. This doctrine prevents a patentee from obtaining a second patent for an invention that is substantially the same as, or an obvious variation of, an invention claimed in an earlier patent held by the same patentee.
In this case, U.S. Patent No. 7,960,390 was issued in 2011. Novo Nordisk likely holds other patents related to liraglutide, potentially including earlier-filed patents covering the composition of matter or earlier methods of use. If Sandoz can demonstrate that the claims of the '390 patent are obvious over claims in an earlier Novo Nordisk patent, and that patent has not expired or been subject to a terminal disclaimer that waives the excess term, the '390 patent could be deemed invalid under this doctrine. This would provide an alternative route for Sandoz to invalidate the asserted patent, independent of prior art existing before the filing date.
What are the potential outcomes of this litigation?
The potential outcomes of the Novo Nordisk Inc. v. Sandoz Inc. litigation include:
- Judgment for Novo Nordisk: If the court finds that Sandoz's proposed generic product infringes U.S. Patent No. 7,960,390 and that the patent is valid, Sandoz will be prohibited from launching its generic product until the patent expires or is otherwise invalidated. This would preserve Novo Nordisk's market exclusivity for Victoza.
- Judgment for Sandoz: If the court finds that Sandoz's product does not infringe the asserted claims, or if the court determines that U.S. Patent No. 7,960,390 is invalid (due to anticipation, obviousness, or other grounds), Sandoz may receive court approval to launch its generic liraglutide product. This would lead to significant price competition and revenue loss for Novo Nordisk.
- Settlement: The parties may reach a settlement agreement before a final court decision. Such settlements often involve a confidential agreement on the terms of generic entry, potentially including a delayed launch date in exchange for certain commercial concessions.
- Appeal: Regardless of the district court's decision, either party may appeal the outcome to the U.S. Court of Appeals for the Federal Circuit, extending the legal dispute.
What is the timeline for potential generic entry if Sandoz prevails?
If Sandoz prevails and successfully invalidates U.S. Patent No. 7,960,390, or establishes non-infringement, the timeline for generic entry would depend on several factors:
- 180-Day Generic Exclusivity: If Sandoz is the first generic challenger to file an ANDA and obtains tentative approval from the FDA, it is typically eligible for 180 days of market exclusivity, during which the FDA cannot approve another generic version of the same drug. [4]
- FDA Approval Process: Following a favorable court ruling, Sandoz would still need to obtain final approval from the Food and Drug Administration (FDA) for its ANDA. This process can take several months.
- Patent Expiration: U.S. Patent No. 7,960,390 has an expiry date of June 14, 2028, with potential for patent term extension. [1] If Sandoz loses on all counts and the patent remains in force until its expiration (including any extensions), generic entry would be deferred until that date.
Given the ongoing litigation, a precise timeline for generic entry is uncertain and contingent on the court's rulings and subsequent FDA actions.
What are the potential impacts on the pharmaceutical market?
The outcome of this litigation has significant implications for the pharmaceutical market:
- Novo Nordisk: A victory would allow Novo Nordisk to maintain its market share and pricing power for Victoza, preserving a substantial revenue stream. A loss would lead to immediate generic competition, significantly impacting Victoza sales and profitability.
- Sandoz (and other generic manufacturers): A successful challenge by Sandoz would open the market for generic liraglutide, leading to lower drug prices for patients and payers. This success could also pave the way for other generic manufacturers to enter the market.
- Diabetes Treatment Landscape: The availability of a lower-cost generic liraglutide would increase access to GLP-1 receptor agonist therapy for a broader patient population, potentially altering treatment prescribing patterns.
- Innovation Incentive: The defense of key patents like the '390 patent by originator companies is seen as crucial for recouping R&D investments and incentivizing future innovation. Conversely, aggressive patent challenges by generic companies aim to reduce healthcare costs.
Key Takeaways
- Novo Nordisk is litigating against Sandoz over Sandoz's proposed generic liraglutide, alleging infringement of U.S. Patent No. 7,960,390.
- Sandoz is defending by challenging the validity of the '390 patent, asserting anticipation and obviousness.
- Victoza is a significant revenue generator for Novo Nordisk, with 2022 global sales exceeding $6 billion USD.
- The litigation is in pre-trial stages, with claim construction being a pivotal phase.
- The outcome will determine the timing of generic liraglutide market entry and impact pricing, competition, and patient access.
Frequently Asked Questions
-
What is the primary drug at the center of this patent dispute?
The primary drug is Victoza (liraglutide), a GLP-1 receptor agonist used to treat type 2 diabetes and reduce cardiovascular risk.
-
What is the specific legal basis for Sandoz's challenge to the patent's validity?
Sandoz is challenging U.S. Patent No. 7,960,390 on the grounds that the claimed invention is anticipated by prior art or would have been obvious to a person skilled in the relevant field at the time of invention.
-
When does U.S. Patent No. 7,960,390 currently expire?
The patent is scheduled to expire on June 14, 2028, although potential patent term extensions could alter this date.
-
Can Sandoz launch its generic drug while this litigation is ongoing?
Generally, Sandoz cannot launch its generic drug if Novo Nordisk prevails on infringement and validity, and the patent remains in force. A favorable ruling for Sandoz, or a settlement allowing for entry, would be required.
-
What is the significance of the Hatch-Waxman Act in this case?
The Hatch-Waxman Act governs the process for generic drug approval and the interplay between generic applications and existing patents. Novo Nordisk's claim is based on Sandoz's ANDA filing under this act.
Citations
[1] Novo Nordisk Inc. v. Sandoz Inc., Case No. 1:20-cv-00747 (D.N.J. April 20, 2020). Complaint for Patent Infringement.
[2] Novo Nordisk Inc. v. Sandoz Inc., Case No. 1:20-cv-00747 (D.N.J. July 27, 2020). Answer and Counterclaims.
[3] Novo Nordisk A/S. (2023, February 1). Annual Report 2022. Retrieved from [Novo Nordisk Investor Relations website or SEC filings]. (Note: Specific URL or filing reference would be ideal if publicly available and stable. Placeholder used.)
[4] U.S. Food and Drug Administration. (n.d.). Generic Drugs: Approval and Exclusivity. Retrieved from [FDA website section on generic drugs]. (Note: Specific URL or page reference would be ideal if publicly available and stable. Placeholder used.)
